Transcutaneous Auricular Vagus Nerve Stimulation Added to Physiotherapy for Adhesive Capsulitis (taVNS-AC)
Effect of Transcutaneous Auricular Vagus Nerve Stimulation Added to Standard Physiotherapy on Pain, Function, and Quality of Life in Patients With Shoulder Adhesive Capsulitis: A Randomized Controlled Trial
This randomized, sham-controlled study will evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS), when added to standard physiotherapy, improves pain, shoulder function, range of motion, and quality of life in adults with adhesive capsulitis.
A total of 40 participants aged 18 to 65 years will be randomly assigned to one of two groups. Both groups will receive 15 sessions of standard physiotherapy over 3 weeks. In addition, one group will receive active taVNS for 30 minutes per day, while the other group will receive sham stimulation for the same duration and frequency. Assessments will be performed before treatment and after the 15th treatment session using pain, shoulder disability, quality-of-life, and shoulder range-of-motion measurements.
調査の概要
状態
条件
詳細な説明
Adhesive capsulitis is a musculoskeletal condition characterized by shoulder pain and progressive restriction of active and passive range of motion. Although physiotherapy, therapeutic exercise, and manual therapy are commonly used, pain relief and functional recovery may be incomplete in some patients. Therefore, additional non-invasive treatment approaches that may enhance the effects of rehabilitation are clinically relevant.
Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique that stimulates the auricular branch of the vagus nerve. It may influence pain modulation, autonomic nervous system regulation, and inflammatory pathways. Previous studies have reported potential benefits of auricular vagus nerve stimulation in several chronic pain conditions; however, evidence regarding its use in adhesive capsulitis remains limited.
The objective of this study is to determine whether active taVNS added to standard physiotherapy provides greater clinical improvement than sham taVNS added to the same physiotherapy program. The main hypothesis is that participants receiving active taVNS will demonstrate greater reductions in pain and shoulder-related disability after treatment. Secondary objectives are to evaluate changes in shoulder range of motion and health-related quality of life and to assess the tolerability of the intervention.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Muhsin Doran, MD
- 電話番号:05340807940
- メール:muhsin-doran@hotmail.com
研究場所
-
-
Istanbul
-
Istanbul、Istanbul、トルコ(Türkiye)、34381
- 募集
- Liv hospital Vadistanbul
-
コンタクト:
- Muhsin Doran, MD
- 電話番号:05340807940
- メール:muhsin-doran@hotmail.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age between 18 and 65 years.
- Clinical diagnosis of adhesive capsulitis confirmed by physical examination and, when clinically indicated, imaging.
- Shoulder pain and limitation of shoulder range of motion for at least 3 months.
- Provision of written informed consent.
- General health status sufficient to participate in standard physiotherapy and active or sham transcutaneous auricular vagus nerve stimulation.
- Ability to comply with the planned treatment sessions and outcome assessments.
Exclusion Criteria:
- Shoulder stiffness secondary to trauma, surgery, infection, or tumor.
- Rotator cuff tear, advanced glenohumeral osteoarthritis, or inflammatory rheumatic disease.
- Glucocorticoid injection into the affected shoulder within the previous 3 months.
- Surgical intervention involving the affected shoulder within the previous 6 months.
- Active infection or skin lesion in the shoulder region.
- Cervical radiculopathy, brachial plexopathy, stroke, or another neurological disorder affecting the upper extremity.
- Presence of a cardiac pacemaker or another implanted electronic device.
- Pregnancy or breastfeeding.
- Serious systemic disease or cognitive impairment that may prevent compliance with the study protocol.
- Known intolerance or previous adverse reaction to transcutaneous electrical stimulation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Standard Physiotherapy Plus Active taVNS
Participants receive 15 sessions of standard physiotherapy over 3 weeks.
Active transcutaneous auricular vagus nerve stimulation is administered for 30 minutes during each treatment session in addition to the physiotherapy program.
|
Active transcutaneous auricular vagus nerve stimulation will be administered for 30 minutes per session during each of 15 treatment sessions over 3 weeks, in addition to standard physiotherapy.
Electrical stimulation will be delivered transcutaneously through an auricular electrode to a vagally innervated region of the external ear.
The physiotherapist administering the stimulation will be aware of group allocation, while participants and the outcomes assessor will remain blinded.
Participants will receive 15 standard physiotherapy sessions over 3 weeks, with five sessions per week.
The program will include pain-relieving physical therapy modalities, glenohumeral and scapulothoracic joint mobilization, passive and active-assisted range-of-motion exercises, capsular stretching, and progressive strengthening exercises for the rotator cuff and scapular stabilizing muscles.
Treatment intensity and exercise progression will be individualized according to pain severity, irritability, and range-of-motion limitations.
The same physiotherapy protocol will be administered to both study arms.
|
|
偽コンパレータ:Standard Physiotherapy Plus Sham taVNS
Participants receive 15 sessions of standard physiotherapy over 3 weeks.
In addition, sham transcutaneous auricular vagus nerve stimulation is administered for 30 minutes with the same frequency and treatment schedule as the active stimulation.
|
Participants will receive 15 standard physiotherapy sessions over 3 weeks, with five sessions per week.
The program will include pain-relieving physical therapy modalities, glenohumeral and scapulothoracic joint mobilization, passive and active-assisted range-of-motion exercises, capsular stretching, and progressive strengthening exercises for the rotator cuff and scapular stabilizing muscles.
Treatment intensity and exercise progression will be individualized according to pain severity, irritability, and range-of-motion limitations.
The same physiotherapy protocol will be administered to both study arms.
Sham transcutaneous auricular vagus nerve stimulation will be administered for 30 minutes per session during each of 15 treatment sessions over 3 weeks, in addition to standard physiotherapy.
The sham procedure will follow the same session frequency and duration as the active intervention but will be applied according to a prespecified sham protocol that is not expected to produce therapeutic vagal stimulation.
The physiotherapist administering the intervention will be aware of group allocation, while participants and the outcomes assessor will remain blinded.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Shoulder Pain and Disability Index (SPADI) Total Score
時間枠:Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
The Shoulder Pain and Disability Index (SPADI) is a 13-item patient-reported questionnaire consisting of a 5-item pain subscale and an 8-item disability subscale.
The total score ranges from 0 to 100, with higher scores indicating greater shoulder pain and disability.
The primary outcome will be the change in the SPADI total score from baseline to the assessment performed after completion of the 15th treatment session.
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Shoulder Pain Intensity Assessed With the Visual Analog Scale (VAS)
時間枠:Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
Shoulder pain intensity will be assessed using a 10-cm Visual Analog Scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Higher scores indicate greater pain intensity.
The outcome will be calculated as the change in VAS score from baseline to the assessment performed after completion of the 15th treatment session.
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
|
Change in Shoulder Flexion Range of Motion
時間枠:Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
Change in Shoulder Flexion Range of Motion Change in Shoulder Abduction Range of Motion Change in Shoulder Extension Range of Motion Change in Shoulder Internal Rotation Range of Motion Change in Shoulder External Rotation Range of Motion Change in Shoulder Horizontal External Rotation Range of Motion Change in Shoulder Horizontal Abduction Range of Motion Change in Shoulder Horizontal Adduction Range of Motion
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
|
Change in Health-Related Quality of Life Assessed With the 36-Item Short Form Health Survey (SF-36)
時間枠:Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36).
The questionnaire evaluates eight domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health.
Each domain is scored from 0 to 100, with higher scores indicating better health-related quality of life.
Changes in domain scores from baseline to the post-treatment assessment will be evaluated.
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Muhsin Doran、Liv hospital Vadistanbul
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。